Lecture 7: Clin Pharm for Neurologic Diseases

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/45

encourage image

There's no tags or description

Looks like no tags are added yet.

46 Terms

1
New cards

GABA-A receptor

  • ligand-gated ion channel

  • binding of GABA causes change in conformation and entrance of Cl-

  • binding sites for GABA, benzodiazepines, barbiturates


2
New cards

diazepam

  • prototypical benzodiazepine

  • many indications

  • highly lipid soluble

  • moderately protein bound

  • schedule IV


3
New cards

diazepam MOA

  • depression of subcortical regions of brain

  • enhances release and binding of GABA

  • diminished release of ACh


4
New cards

diazepam PO

  • rapidly absorbed with high 1st pass effect

  • not recommended in cats


5
New cards

diazepam injectable

  • unpredictable IM or SQ

  • binds to plastic, light sensitive


6
New cards

what is the best 1st choice in ER situations IV?

diazepam

7
New cards

midazolam

  • some effects of diazepam

  • water soluble, but lipid soluble at body pH

  • about 2x stronger

  • main indications → anesthetic, anti-seizure


8
New cards

midazolam injectable

  • can be given IM or SQ

  • somewhat light sensitive


9
New cards

phenobarbital

  • considered broad spectrum

  • MOA → increases neuronal responsiveness to GABA

  • hydroxylated oxidation occurs in the liver, cytochrome P450 pathway

  • reaches steady state in 10-14 days

  • t ½ of 54-72 hrs in dogs


10
New cards

phenobarbital adjustments if seizures still frequent and/or levels low

  • adjust dose

  • if pheno level > 30 ug/ml, consider additional drug


11
New cards

if weaning anticonvulsant drugs

  • never abruptly d/c

  • decrease by 25% every 2 weeks


12
New cards

bromide

  • acceptable 2nd line drug, questionable 1st line

  • anti-seizure effects over 150 years old

  • salt

  • MOA → thought to compete with Cl- at GABA gated ion channel; hyperpolarizes cells


13
New cards

bromide half life

  • 90% after 2 months

  • full steady state after 3-4 months


14
New cards

bromide therapeutic monitoring

  • done 1 week after load, or 3 months after maintenance

  • level should be 1-3 mg/ml


15
New cards

what can affect bromide levels?

chloride

16
New cards

zonisamide

  • sulfonamide drug approved in USA

  • used as 3rd medication

  • MOA → blocks Na+ channels, blockage of T-type Ca2+ channels, inhibit presynaptic glutamate

  • suppresses hypersynchronization

  • no effect on GABA


17
New cards

zonisamide half life

  • 15 hours in dogs

  • 33 hours in cats


18
New cards

zonisamide metabolism

  • microsomal hepatic enzymes

  • mostly excreted by kidneys

  • affected by phenobarbital

  • may lower total T4 levels


19
New cards

levetiracetam

  • approved for humans

  • MOA→ not well understood, binds to synaptic vesicles protein SV2A, regulation of vesicle exocytosis, selectively prevent hypersynchronization


20
New cards

levetiracetam half life

2-5 hours regular, 4-5 hours XR


21
New cards

levetiracetam metabolism

  • not heavily metabolized, most renally excreted unchanged

  • affected by phenobarbital (increases clearance)


22
New cards

topiramate

  • wide range of uses

  • considered broad spectrum

  • MOA → voltage-gated Na+ and Ca2+ channels, GABA-A receptor, AMPA/kainite receptors, carbonic anhydrase isoenzymes


23
New cards

topiramate half life

3 hours

24
New cards

topiramate metabolism

through both renal elimination and hepatic biotransformation

25
New cards

possible anticonvulsants

  • gabapentin → binds alpha2S subunit of Ca2+ channels, usually used for neuropathic pain

  • pregabalin

  • felbamate → inhibits excitatory transmission (NMDA)


26
New cards

imepitoin

  • officially an imidazolone

  • MOA → low-affinity partial agonis at BZD site

  • only 10-20% as strong as diazepam

  • dose-dependently blocks VG Ca2+ channels

  • half life is 2 hours

  • metabolism → hepatic induction


27
New cards

meclizine

  • antihistamine used for disequilibrium and motion sickness

  • central anticholinergic

  • depresses vestibular stimulation

  • CRTZ in medulla


28
New cards

diazepam for vestibular disease

  • peripheral dz → otitis media/interna, idiopathic → general suppression of normal vestibular function

  • central dz → vascular, MUE, neoplasia, flagyl → GABA-minergic receptors in cerebellum and brainstem nuclei


29
New cards

maropitant (cerenia)

  • neurokinin 1 receptor antagonist which acts by inhibiting the binding of substance P

  • substance P found in significant concentrations in the nuclei comprising the emetic center and is considered the key neurotransmitter involved in emesis


30
New cards

substance P

  • stimulates vomiting mechanism

  • pain transmission in spinal cord

  • anxiety and depression

  • propagates inflammation


31
New cards

maropitant metabolism

  • mainly by CYP450 enzyme

  • pathway become saturated so < 5 day course

  • need 2 day rest period


32
New cards

ondansetron

  • zofran!

  • reduces nausea and vomiting

  • selective serotonin 5HT3 receptor antagonist → at vagus nerve, CRTZ of area postrema


33
New cards

immune modifers are used to

  • reduce vasogenic edema

  • reduce CSF production

  • immunosuppression


34
New cards

cytarabine

  • FDA approved

  • leukemias and lymphomas

  • antimetabolite


35
New cards

cytarabine MOA

  • s-phase → interferes with DNA synthesis/replication

  • mimics deoxycytidine

  • weak inhibitor of DNA polymerase


36
New cards

main indications of cytarabine in vet med

  • inflammatory CNS disease → autoimmune

  • steroid-responsive meningitis/arteritis

  • lymphoma


37
New cards

cytarabine side effects

  • minimal

  • possible myelosuppression

  • CBC at 7 days post treatment


38
New cards

leflunomide

  • FDA approved

  • rheumatoid and psoriatic arthritis

  • immune-mediated polyarthritis in dogs

  • prodrug → active teriflunomide


39
New cards

leflunomide MOA

  • inhibits reproduction of rapidly dividing cells

  • suppresses immunoglobulin production

  • reduces inflammatory cytokines

  • reduces leukocyte adhesion and diapedesis


40
New cards

lomustine

  • highly lipid soluble

  • cell cycle non-specific alkylating agent → damage to nucleic acid results in breakage during replication → apoptosis


41
New cards

lomustine main indications

  • inflammatory brain disease

  • lymphoma or glial neoplasia


42
New cards

lomustine adverse effects

  • bone marrow suppression

  • GI → diarrhea, vomiting

  • hepatopathy


43
New cards

cyclosporine

  • isolated from fungus in early 70s

  • main use is to reduce transplant rejection and treat autoimmune diseases

  • calcineurin inhibitor → results in reduction in cytokine production by T-cells


44
New cards

cyclosporine monitoring

  • plasma levels highly variable

  • IL-2 suppression assay at MSU → assesses the response of the animal to the drug


45
New cards

pyridostigmine

  • ACh inhibitor

  • MOA → prolongs action of ACh in the synaptic cleft

  • mainly used to treat myasthenia gravis


46
New cards

misoprostol

  • synthetic prostaglandin E analogue

  • inhibits gastric parietal cells

  • rapid absorption and onset of action

  • side effects → diarrhea, stomach cramping, abortifacient